Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACTS: Eltrombopag with r-ATG and cyclosporine in treatment-naive severe aplastic anemia (East Asian)
jRCT2080225339Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in aplastic anemia, sponsored by Novartis. Started Aug 2020; status: completed.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on jRCT2080225339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225339.